Updating results

1132 results

Sort: Relevance | Date

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Technology appraisal guidance Published August 2018

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Technology appraisal guidance Published May 2003

Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

Technology appraisal guidance Published January 2004

Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for treating heavy menstrual bleeding (HMB)

Technology appraisal guidance Published April 2004

Obeticholic acid for treating primary biliary cholangitis (TA443)

Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults

Technology appraisal guidance Published April 2017

Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

Evidence-based recommendations on paclitaxel (Taxol) for treating ovarian cancer

Technology appraisal guidance Published January 2003 Last updated May 2005

Guidance on the use of electroconvulsive therapy (TA59)

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

Technology appraisal guidance Published April 2003 Last updated October 2009

Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published October 2016

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Technology appraisal guidance Published March 2017

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)

NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance Published March 2017

Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

Evidence-based recommendations on human growth hormone (somatropin) for treating growth failure in children

Technology appraisal guidance Published May 2010

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

Technology appraisal guidance Published May 2010

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

Technology appraisal guidance Published August 2009

Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (TA20)

Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)

Technology appraisal guidance Published January 2001

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

Technology appraisal guidance Published November 2010

Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence

Technology appraisal guidance Published October 2010

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C

Technology appraisal guidance Published September 2010

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

Technology appraisal guidance Published August 2010

Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer..

Technology appraisal guidance Published January 2012

Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

Evidence-based recommendations on topotecan (Hycamtin) for treating relapsed small-cell lung cancer (SCLC)

Technology appraisal guidance Published November 2009

Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip

Technology appraisal guidance Published February 2014

HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)

Technology appraisal guidance Published July 2005

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Technology appraisal guidance Published February 2016

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

Evidence-based recommendations on olaparib (Lynparza)

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

Technology appraisal guidance Published November 2013

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Technology appraisal guidance Published July 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

Technology appraisal guidance Published November 2013

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..

Technology appraisal guidance Published February 2015

Laparoscopic surgery for colorectal cancer (TA105)

Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer

Technology appraisal guidance Published August 2006

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block

Technology appraisal guidance Published February 2005 Last updated November 2014

Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)

Technology appraisal guidance Published October 2004 Last updated November 2010

Laparoscopic surgery for inguinal hernia repair (TA83)

Evidence-based recommendations on laparoscopic (keyhole) surgery for repairing inguinal hernia (hernia in groin)

Technology appraisal guidance Published September 2004

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

Technology appraisal guidance Published March 2002

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

Technology appraisal guidance Published April 2004

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017